Proposed new approach for treating Paget's disease of bone.

Hdl Handle:
http://hdl.handle.net/10147/135457
Title:
Proposed new approach for treating Paget's disease of bone.
Authors:
Mahmood, W; McKenna, M J
Affiliation:
St. Michaels Hospital, Lower George's Street, Dún Laoghaire, Co. Dublin, Ireland.
Citation:
Proposed new approach for treating Paget's disease of bone. 2011, 180 (1):121-4 Ir J Med Sci
Journal:
Irish journal of medical science
Issue Date:
Mar-2011
URI:
http://hdl.handle.net/10147/135457
DOI:
10.1007/s11845-010-0652-6
PubMed ID:
21132539
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21132539
Abstract:
Paget's disease of the bone (PDB) is a localized disorder of bone remodeling. Nitrogen-containing bisphosphonates (N-BPs) are the treatment of choice.; We aimed to determine the effectiveness of N-BPs in our practice.; We prospectively tabulated clinical, imaging and biochemical data as well as interventions.; All patients (n = 31) received one or more different N-BPs such as alendronate, risedronate, and zoledronic acid (ZA). Median (absolute range) serum total alkaline phosphatase (ALP) declined from 302 (55-1,600) to 69 (37-101) IU/L. In a subgroup of patients (n = 18) who received ZA after receiving an oral N-BP, median serum total ALP declined from 197 (44-1, 603) to 65 (37-95) IU/L.; Newly diagnosed patients with PDB should be treated for 6 months with oral N-BPs prior to administration of intravenous ZA. Repeat ZA infusions are necessary only if the serum total ALP levels rise above normal, or if symptoms or complications attributable to PDB persist.
Item Type:
Article
Language:
en
MeSH:
Adult; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Male; Middle Aged; Osteitis Deformans
ISSN:
1863-4362

Full metadata record

DC FieldValue Language
dc.contributor.authorMahmood, Wen
dc.contributor.authorMcKenna, M Jen
dc.date.accessioned2011-07-06T15:06:25Z-
dc.date.available2011-07-06T15:06:25Z-
dc.date.issued2011-03-
dc.identifier.citationProposed new approach for treating Paget's disease of bone. 2011, 180 (1):121-4 Ir J Med Scien
dc.identifier.issn1863-4362-
dc.identifier.pmid21132539-
dc.identifier.doi10.1007/s11845-010-0652-6-
dc.identifier.urihttp://hdl.handle.net/10147/135457-
dc.description.abstractPaget's disease of the bone (PDB) is a localized disorder of bone remodeling. Nitrogen-containing bisphosphonates (N-BPs) are the treatment of choice.-
dc.description.abstractWe aimed to determine the effectiveness of N-BPs in our practice.-
dc.description.abstractWe prospectively tabulated clinical, imaging and biochemical data as well as interventions.-
dc.description.abstractAll patients (n = 31) received one or more different N-BPs such as alendronate, risedronate, and zoledronic acid (ZA). Median (absolute range) serum total alkaline phosphatase (ALP) declined from 302 (55-1,600) to 69 (37-101) IU/L. In a subgroup of patients (n = 18) who received ZA after receiving an oral N-BP, median serum total ALP declined from 197 (44-1, 603) to 65 (37-95) IU/L.-
dc.description.abstractNewly diagnosed patients with PDB should be treated for 6 months with oral N-BPs prior to administration of intravenous ZA. Repeat ZA infusions are necessary only if the serum total ALP levels rise above normal, or if symptoms or complications attributable to PDB persist.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21132539en
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAlgorithms-
dc.subject.meshBone Density Conservation Agents-
dc.subject.meshDiphosphonates-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshOsteitis Deformans-
dc.titleProposed new approach for treating Paget's disease of bone.en
dc.typeArticleen
dc.contributor.departmentSt. Michaels Hospital, Lower George's Street, Dún Laoghaire, Co. Dublin, Ireland.en
dc.identifier.journalIrish journal of medical scienceen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.